Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Stiffness | 9 | 2023 | 77 | 4.740 |
Why?
|
| Blood Pressure | 18 | 2023 | 1467 | 3.910 |
Why?
|
| Hypertension | 16 | 2023 | 1503 | 3.860 |
Why?
|
| Dyslipidemias | 12 | 2023 | 235 | 3.060 |
Why?
|
| Adipokines | 3 | 2017 | 96 | 1.700 |
Why?
|
| Cardiovascular Diseases | 12 | 2023 | 2195 | 1.570 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2022 | 52 | 1.570 |
Why?
|
| Pulse Wave Analysis | 7 | 2023 | 45 | 1.500 |
Why?
|
| Aortic Coarctation | 2 | 2023 | 103 | 1.460 |
Why?
|
| Obesity | 9 | 2023 | 2884 | 1.440 |
Why?
|
| Hypolipidemic Agents | 3 | 2016 | 190 | 1.420 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2023 | 112 | 1.320 |
Why?
|
| Echocardiography | 4 | 2019 | 1182 | 1.270 |
Why?
|
| Lipids | 4 | 2020 | 644 | 1.210 |
Why?
|
| Rheumatic Heart Disease | 2 | 2018 | 44 | 1.140 |
Why?
|
| Atherosclerosis | 3 | 2023 | 935 | 1.040 |
Why?
|
| Mass Screening | 4 | 2021 | 1509 | 1.040 |
Why?
|
| Pediatric Obesity | 3 | 2020 | 364 | 1.000 |
Why?
|
| Pediatrics | 5 | 2021 | 1141 | 0.900 |
Why?
|
| Ductus Arteriosus | 1 | 2023 | 40 | 0.890 |
Why?
|
| Adolescent | 36 | 2023 | 31252 | 0.880 |
Why?
|
| Hyperinsulinism | 1 | 2023 | 85 | 0.870 |
Why?
|
| Hemodynamics | 4 | 2017 | 935 | 0.840 |
Why?
|
| Body Mass Index | 7 | 2021 | 2203 | 0.830 |
Why?
|
| Life Style | 3 | 2021 | 612 | 0.820 |
Why?
|
| Insulin Resistance | 3 | 2023 | 731 | 0.810 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2021 | 5 | 0.800 |
Why?
|
| Aorta | 3 | 2023 | 692 | 0.790 |
Why?
|
| Metabolic Syndrome | 4 | 2021 | 353 | 0.760 |
Why?
|
| Child | 32 | 2023 | 29154 | 0.730 |
Why?
|
| Hyperglycemia | 1 | 2023 | 333 | 0.730 |
Why?
|
| Risk Factors | 21 | 2023 | 17523 | 0.700 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 295 | 0.700 |
Why?
|
| Referral and Consultation | 2 | 2016 | 899 | 0.690 |
Why?
|
| Lead | 1 | 2018 | 54 | 0.640 |
Why?
|
| Manometry | 1 | 2017 | 74 | 0.630 |
Why?
|
| Child of Impaired Parents | 1 | 2017 | 17 | 0.610 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 109 | 0.580 |
Why?
|
| Cross-Sectional Studies | 9 | 2019 | 4314 | 0.570 |
Why?
|
| American Heart Association | 8 | 2023 | 310 | 0.570 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 44 | 0.570 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 1697 | 0.550 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 546 | 0.550 |
Why?
|
| Body Weight | 1 | 2020 | 1293 | 0.540 |
Why?
|
| Office Visits | 1 | 2016 | 97 | 0.540 |
Why?
|
| Male | 44 | 2023 | 123000 | 0.530 |
Why?
|
| Models, Econometric | 1 | 2015 | 13 | 0.530 |
Why?
|
| Longitudinal Studies | 6 | 2023 | 1945 | 0.520 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 14 | 0.510 |
Why?
|
| Population Surveillance | 1 | 2018 | 627 | 0.510 |
Why?
|
| Humans | 60 | 2023 | 261506 | 0.490 |
Why?
|
| Young Adult | 13 | 2023 | 21445 | 0.490 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2016 | 192 | 0.490 |
Why?
|
| Markov Chains | 1 | 2015 | 175 | 0.490 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2011 | 42 | 0.490 |
Why?
|
| Biomarkers | 10 | 2019 | 5047 | 0.480 |
Why?
|
| Heart Rate | 1 | 2017 | 737 | 0.480 |
Why?
|
| Female | 42 | 2023 | 141928 | 0.470 |
Why?
|
| Accessory Atrioventricular Bundle | 1 | 2012 | 7 | 0.450 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 48 | 0.440 |
Why?
|
| Primary Prevention | 1 | 2014 | 255 | 0.430 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 289 | 0.430 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 34 | 0.430 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 849 | 0.420 |
Why?
|
| Ventricular Fibrillation | 1 | 2012 | 61 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 212 | 0.410 |
Why?
|
| Electronic Health Records | 2 | 2017 | 929 | 0.410 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 196 | 0.400 |
Why?
|
| Incidence | 7 | 2021 | 5673 | 0.400 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 1054 | 0.400 |
Why?
|
| Medication Adherence | 1 | 2016 | 492 | 0.390 |
Why?
|
| Triglycerides | 3 | 2020 | 603 | 0.380 |
Why?
|
| Health Policy | 1 | 2013 | 291 | 0.360 |
Why?
|
| Prevalence | 7 | 2018 | 3260 | 0.360 |
Why?
|
| Tachycardia, Ventricular | 1 | 2012 | 239 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 2403 | 0.340 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2009 | 88 | 0.330 |
Why?
|
| Sex Factors | 4 | 2020 | 2139 | 0.330 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 4298 | 0.320 |
Why?
|
| Retinol-Binding Proteins, Plasma | 2 | 2017 | 14 | 0.310 |
Why?
|
| alpha-2-HS-Glycoprotein | 2 | 2017 | 10 | 0.310 |
Why?
|
| Arterial Pressure | 2 | 2019 | 107 | 0.310 |
Why?
|
| United States | 13 | 2023 | 15433 | 0.310 |
Why?
|
| Receptors, Leptin | 2 | 2017 | 62 | 0.300 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2017 | 52 | 0.300 |
Why?
|
| Cholesterol, HDL | 3 | 2020 | 341 | 0.300 |
Why?
|
| Catheter Ablation | 1 | 2012 | 620 | 0.300 |
Why?
|
| Adiponectin | 2 | 2017 | 163 | 0.280 |
Why?
|
| Heart Diseases | 1 | 2012 | 732 | 0.280 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 79 | 0.270 |
Why?
|
| Myocardium | 2 | 2012 | 1313 | 0.270 |
Why?
|
| Adult | 17 | 2023 | 77950 | 0.270 |
Why?
|
| Leptin | 2 | 2017 | 295 | 0.270 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 499 | 0.260 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 1323 | 0.250 |
Why?
|
| Heart Ventricles | 2 | 2009 | 846 | 0.250 |
Why?
|
| Diet | 2 | 2023 | 1440 | 0.240 |
Why?
|
| Facial Pain | 1 | 2003 | 20 | 0.230 |
Why?
|
| Facial Paralysis | 1 | 2003 | 60 | 0.220 |
Why?
|
| Prospective Studies | 8 | 2019 | 12873 | 0.220 |
Why?
|
| Massachusetts | 3 | 2019 | 106 | 0.220 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2009 | 705 | 0.210 |
Why?
|
| Amlodipine | 1 | 2021 | 22 | 0.210 |
Why?
|
| Migraine Disorders | 1 | 2003 | 79 | 0.210 |
Why?
|
| Masked Hypertension | 1 | 2021 | 1 | 0.210 |
Why?
|
| Boston | 4 | 2017 | 108 | 0.210 |
Why?
|
| Longevity | 1 | 2023 | 154 | 0.210 |
Why?
|
| Insulin | 2 | 2023 | 1454 | 0.210 |
Why?
|
| White Coat Hypertension | 1 | 2021 | 10 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2017 | 2316 | 0.200 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 38 | 0.200 |
Why?
|
| Receptor, TIE-2 | 2 | 2012 | 82 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2018 | 37905 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 945 | 0.190 |
Why?
|
| Antihypertensive Agents | 2 | 2021 | 395 | 0.180 |
Why?
|
| Regression Analysis | 2 | 2020 | 1546 | 0.180 |
Why?
|
| Age Factors | 6 | 2019 | 5377 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2023 | 6869 | 0.180 |
Why?
|
| Logistic Models | 2 | 2017 | 3441 | 0.170 |
Why?
|
| Cardiovascular System | 1 | 2020 | 145 | 0.170 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 67 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 14889 | 0.170 |
Why?
|
| Reference Values | 1 | 2020 | 1099 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2016 | 2218 | 0.160 |
Why?
|
| Brazil | 1 | 2018 | 165 | 0.160 |
Why?
|
| Alanine Transaminase | 1 | 2019 | 227 | 0.160 |
Why?
|
| Child, Preschool | 6 | 2021 | 16273 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 187 | 0.150 |
Why?
|
| Pulse | 1 | 2017 | 31 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 29 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 228 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2017 | 100 | 0.150 |
Why?
|
| Cardiology | 1 | 2023 | 530 | 0.150 |
Why?
|
| Creatine Kinase | 1 | 2017 | 92 | 0.150 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 193 | 0.150 |
Why?
|
| Coronary Disease | 3 | 2011 | 764 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 1362 | 0.150 |
Why?
|
| Glucose | 1 | 2023 | 1248 | 0.140 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 565 | 0.140 |
Why?
|
| Middle Aged | 11 | 2017 | 86204 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4892 | 0.140 |
Why?
|
| Muscular Diseases | 1 | 2017 | 161 | 0.140 |
Why?
|
| Health Behavior | 2 | 2020 | 603 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2018 | 288 | 0.130 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2016 | 105 | 0.130 |
Why?
|
| Northern Territory | 1 | 2015 | 1 | 0.130 |
Why?
|
| Penicillin G Benzathine | 1 | 2015 | 16 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2017 | 9244 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2017 | 1244 | 0.130 |
Why?
|
| Rheumatic Fever | 1 | 2015 | 18 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 70 | 0.130 |
Why?
|
| Benchmarking | 1 | 2016 | 273 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2016 | 700 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 891 | 0.120 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 78 | 0.120 |
Why?
|
| Drug Recalls | 1 | 2013 | 4 | 0.120 |
Why?
|
| Patient Identification Systems | 1 | 2013 | 9 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2014 | 48 | 0.120 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 226 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 250 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 435 | 0.120 |
Why?
|
| Drug Contamination | 1 | 2013 | 52 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 551 | 0.120 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 96 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 181 | 0.110 |
Why?
|
| Pedigree | 1 | 2017 | 1890 | 0.110 |
Why?
|
| Exercise | 1 | 2021 | 1183 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 1183 | 0.110 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2012 | 43 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 58 | 0.110 |
Why?
|
| Health Promotion | 1 | 2016 | 502 | 0.100 |
Why?
|
| Electrophysiology | 1 | 2012 | 333 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 475 | 0.100 |
Why?
|
| Recurrence | 2 | 2015 | 4758 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2012 | 153 | 0.100 |
Why?
|
| Prognosis | 3 | 2019 | 21713 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 256 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 227 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2015 | 554 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 360 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 1011 | 0.090 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 386 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2013 | 467 | 0.090 |
Why?
|
| Truncus Arteriosus | 1 | 2009 | 14 | 0.090 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.090 |
Why?
|
| Pyrroles | 1 | 2013 | 576 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 630 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 1489 | 0.080 |
Why?
|
| Fibrosis | 1 | 2012 | 793 | 0.080 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2009 | 133 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 2522 | 0.080 |
Why?
|
| Tetralogy of Fallot | 1 | 2009 | 149 | 0.080 |
Why?
|
| Genotype | 1 | 2016 | 4109 | 0.080 |
Why?
|
| Aging | 2 | 2010 | 1582 | 0.080 |
Why?
|
| Phenotype | 1 | 2019 | 6295 | 0.080 |
Why?
|
| Heart Atria | 1 | 2010 | 352 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2009 | 348 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2021 | 32848 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2013 | 1863 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 412 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2009 | 749 | 0.070 |
Why?
|
| HIV Infections | 1 | 2018 | 2134 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6100 | 0.070 |
Why?
|
| Reoperation | 1 | 2009 | 1382 | 0.060 |
Why?
|
| Aged | 4 | 2017 | 70117 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.060 |
Why?
|
| Time Factors | 2 | 2015 | 12926 | 0.060 |
Why?
|
| Canada | 1 | 2023 | 429 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2992 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2002 | 1374 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2023 | 337 | 0.050 |
Why?
|
| Latin America | 1 | 2021 | 115 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.040 |
Why?
|
| Private Sector | 1 | 2019 | 32 | 0.040 |
Why?
|
| Financing, Government | 1 | 2019 | 40 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 1999 | 108 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 173 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2023 | 674 | 0.040 |
Why?
|
| Serum | 1 | 2018 | 68 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 1999 | 248 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 473 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2018 | 240 | 0.040 |
Why?
|
| Troponin T | 1 | 2018 | 261 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 343 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 4988 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 770 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 527 | 0.030 |
Why?
|
| Infant | 2 | 2021 | 13310 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 750 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2002 | 6942 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 498 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 590 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 4971 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1225 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 1972 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 330 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5687 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2016 | 712 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 2809 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 7222 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 512 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 690 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8223 | 0.020 |
Why?
|
| Heart Failure | 1 | 2002 | 2516 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4320 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 2440 | 0.020 |
Why?
|
| Survival Rate | 2 | 2009 | 12221 | 0.010 |
Why?
|
| Captopril | 1 | 2002 | 34 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 719 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 54 | 0.010 |
Why?
|
| Ligation | 1 | 2002 | 193 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6207 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 2002 | 195 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 257 | 0.010 |
Why?
|
| Animals | 3 | 2016 | 59536 | 0.010 |
Why?
|
| Mice | 2 | 2002 | 34495 | 0.010 |
Why?
|